FDA Clearance Tracker · DEN230052
Eversense AP CGM System
Last checked: Nov 20, 2026Latest source record: Apr 29, 2024 (this decision)Source: openFDAMethods & limitations
Decided
Apr 29, 2024
De Novo granted
Time to decision
264 days
Received Aug 9, 2023. Calendar days, including time FDA spent waiting on the applicant.
Pathway
De Novo
Direct
Device class
Class II
The decision
- FDA number
- DEN230052
- Device name
- Eversense AP CGM System
- Applicant
- Senseonics, Incorporated
- Applicant location
- Germantown, MD
- Received
- Aug 9, 2023
- Decided
- Apr 29, 2024
- Decision
- De Novo granted
- Submission type
- Direct
Device type
- Device type
- Integrated Continuous Glucose Monitoring System With Sensor Containing Dexamethasone Acetate (SBA)
- Device class
- Class II
- Regulation
- 21 CFR 862.1357
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- FDA granted this as a De Novo request, which means it created a new device type. There was no existing device to compare it to.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
- FDA database record for DEN230052
- Decision summary (PDF) · FDA posts these some weeks after the decision, so a recent one may not open yet.
Other decisions for Senseonics, Incorporated
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K241335 · Decided Sep 16, 2024 · 126 days after receipt
Device type: Integrated Continuous Glucose Monitoring System With Sensor Containing Dexamethasone Acetate (SBA) · Laboratory Medicine & Pathology
- Eversense® E3 Continuous Glucose Monitoring (CGM) SystemPMA supplement
P160048-S021 · Decided Mar 29, 2023 · 180 days after receipt · Panel Track
Device type: Sensor, glucose, implanted, non-adjunctive use (QHJ) · Laboratory Medicine & Pathology
- Eversense® E3 Continuous Glucose Monitoring SystemPMA supplement
P160048-S016 · Decided Feb 10, 2022 · 498 days after receipt · Panel Track
Device type: Sensor, glucose, implanted, non-adjunctive use (QHJ) · Laboratory Medicine & Pathology
2 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.